Damora Therapeutics, Inc. DMRA R3KPHARMA
Company Overview
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.03.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +768.15% |
| 6 Months: | +1.67% |
| 3 Months: | +39.50% |
| 1 Month: | -2.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DMRA Damora Therapeutics, Inc. R3KPHARMA | 29.17 | -112.19 | $1.80B | 0.00% | -87.69% | -99.74% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 4.83M | -5.83M | -6.34M | -10.17M | -13.55M | -12.27M | -12.94M | -16.94M | -17.12M | -13.62M | -13.49M | -11.16M | -8.58M | -5.74M | -5.58M | -3.84M | -2.60M | -3.42M | -3.16M | -30.81M |
| Net Income | -4.11M | -5.67M | -5.93M | -11.65M | -13.35M | -12.30M | -12.70M | -16.94M | -16.89M | -13.73M | -12.99M | -10.74M | -8.14M | -5.48M | -5.34M | -3.88M | -2.53M | -3.44M | -3.13M | -27.78M |
| Diluted EPS | - | - | - | - | - | - | -0.50 | -0.67 | -0.67 | -0.54 | -0.51 | -0.41 | -7.50 | -5.05 | -4.92 | -3.39 | -1.92 | -2.60 | -2.36 | -0.62 |
| R&D Expense | 3.67M | 4.71M | 4.51M | 7.65M | 9.99M | 8.63M | 9.75M | 13.23M | 13.71M | 10.49M | 10.36M | 8.09M | 2.55M | 2.46M | 1.83M | 1.09M | 678.00K | 1.47M | 1.42M | 23.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | 38.97M | -33.64M | -52.23M | -61.21M | -39.91M | -22.26M | -210.87M |
| Net Income | -36.51M | -34.84M | -51.75M | -61.62M | -38.35M | -21.44M | -209.84M |
| Diluted EPS | - | - | -2.05 | -2.43 | -36.08 | -18.53 | 3.98 |
| R&D Expense | 19.74M | 24.63M | 38.49M | 48.21M | 23.77M | 6.40M | 26.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 56.61M | 171.60M | - | 73.19M | 38.23M | 17.13M | 260.53M |
| Current Assets | - | - | - | - | 63.91M | 36.77M | 16.84M | 260.42M |
| Cash & Equivalents | - | 11.29M | 163.58M | - | 32.79M | 21.46M | 14.18M | 257.62M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 1.38M | 1.72M | 881.00K | 899.00K |
| Total Liabilities | - | 8.14M | 6.11M | - | 11.44M | 5.90M | 1.30M | 20.15M |
| Current Liabilities | - | 7.93M | 5.57M | - | 11.11M | 5.83M | 1.20M | 20.07M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 804.00K | 249.00K | 73.00K | 68.00K |
| Total Equity | -33.84M | -71.15M | 165.49M | - | 61.75M | 32.33M | 15.83M | 240.38M |
| Shares Outstanding | - | - | - | - | 1.03M | 1.08M | 1.32M | 1.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.33M | -38.20M | - | -42.93M | -36.91M | -18.62M | -6.73M |
| Investing Cash Flow | -326.00K | - | - | 12.38M | 22.33M | 11.65M | -17.37M |
| Financing Cash Flow | - | 187.39M | - | 507.00K | 2.88M | 0 | 266.84M |
| Capital Expenditure | - | - | -223.00K | -196.00K | - | - | - |
| Free Cash Flow | - | - | - | -43.13M | -36.91M | -18.62M | -6.73M |
| Net Change in Cash | - | - | - | -30.04M | -11.71M | -6.97M | 242.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 51.3% | -21.1% | - | -99.8% | -118.6% | -135.4% | -87.3% |
| ROCE % | 80.1% | -20.3% | - | -98.6% | -123.2% | -139.7% | -87.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Price (T.Rowe) Associates Inc | 0.08% | 48.74K | $1.10M |
| 2 | Rothschild Investment LLC | - | 34 | $768 |
| 3 | Harbour Investments, Inc. | - | 40 | $903 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMRA
Technical Reactions to DMRA Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQaDk3TlBIanF4LUQ4cm8wUkZISnF0ZG9tOW1lMENCZGJFNmoxSmctbm9JeTFTa2FISXV6cmprd1VWeFNiV0FGVGdmbUpMM1pKb3EtYzRfUmV3TlZHV2NLbTNTRTh3UTMyaDFpMHg0Q2pndnFVQnJRd19oc0dfWUxOMXBSYzc2TFFtdHRGUG…
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1COU0tS0puc21fQnBoai1oRTNPcFNHdV9OSEtJekFKanFRQ2lKUTJ1RHVvVnQ2YkRnU3JqR2tCclBGR0tReW94Y1ZJNjVOelpxYm92eUJsWE1GSmx1?oc=5" target="_blank">DAMORA THERAPEUT (DMRA) Stock News, Mar 19-…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBidjltcEpDUTJ3d3ZqS2Fqdkd4WGl3TEEtMXRnTFd3TllUSnZjYWZWa1pJRFIwWHlyWjhJdTVzMnplQ0pQcUpveUVhTDVpcE4t?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNVE1CVGM5QktKY0I5LVZSUldaRDRBLWtGMUNvZzFYaG14eWQ3R09STWNwNTZQUlFzalNtM2xsMzJtckxhcldoU1ZYbnBJVUJpNW5vbUYxMFJjbXB6bzJwR19OUHh6c3E1cjdTejZkMzBkTUVhd1Zqc2puRUNaVC1UckJfYUhhU3lFaXhRZ0…
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE45cVJpWjdsTzhRT1V2dk1EcGpmUnVxLXVOWUtyb1R5alo0SW1GdGdpZ3RxNjZ5Wk5uSG5MazlkZVVmYzhHOHp1c3JkeGlYRF9ydHpVNGg1ZXpqZ3VsSXVJX2dvSkk2UQ?oc=5" target="_blank">Damora Therapeutics, Inc. Com…
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts | DMRA Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYW90SEY1N1JyLWFaMHBvTU1Ib1dfMW1kbXk1Qjc0djhnNUlyb20wQ2hKVmJLcXl4VWNuMmpGQU43ZVJwdmdBVkUxQjIxNUxpUWZ4cTVsSHRzYTJoOVhLQndsYVh0dGpRcEJtdjJtNEdmS3hkSjZVQlJnaFkzUFZRclQ0eDI4czR0SE8xWW…
DMRA — Frequently Asked Questions
What is the current share price of Damora Therapeutics, Inc. (DMRA)?
As of 2026-09-19 21:16 PDT, Damora Therapeutics, Inc. (DMRA) trades at $29.17 on NasdaqCM. Its 52-week range is $2.58 to $34.14.
What is the market capitalisation of DMRA?
Damora Therapeutics, Inc. (DMRA) has a market capitalisation of $1.80B on NasdaqCM.
What is the P/E ratio of DMRA?
DMRA trades at a trailing price-to-earnings (P/E) ratio of -112.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.20.
What is the return on equity (ROE) of DMRA?
DMRA has a return on equity (ROE) of -99.74%. Its return on capital employed (ROCE) is -87.69%.
Is DMRA a good stock to buy?
This page provides a data-driven analysis of Damora Therapeutics, Inc. (DMRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.